ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 —— Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated disea…